Sensyne Health plc announced unaudited consolidated earnings results for the six months ended October 31, 2018. For the period, the company reported revenues of £39,000 against £20,000 a year ago. Operating loss was £10,334,000 against £3,396,000 a year ago. Loss for the period attributable to owners of the parent was £13,309,000 compared to £43,838,000 a year ago. Loss per share from continuing operations attributable to owners of the parent during the period was £0.10 compared to £0.04 a year ago. Loss from continuing operations was £10,334,000 compared to £3,388,000 a year ago.

In line with the expectations set at the IPO, the company expects to continue to expand the recruitment of its team to support and progress increasing commercial activity and deliver on internal and external R&D programmes leading to an increased operating loss for the remainder of the year 2018.